Top Markets
Coin of the day
Algernon Pharmaceuticals Inc. Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Inc.

AGN
Rank in Stocks #38375
Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company... Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing new treatments. Their research and development efforts concentrate on a range of serious conditions, including non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19, operating across Canada and Australia. The company's primary drug candidate, NP-120, acts as an N-methyl-d-aspartate (NMDA) receptor glutamate antagonist. This compound specifically targets the NMDA-type subunit 2B (Glu2NB) and also demonstrates agonist activity for the Sigma-1 receptor, a chaperone protein elevated during endoplasmic reticulum stress. Furthermore, Algernon is advancing AP-188, a psychedelic agent from the tryptamine family, for treating ischemic stroke in humans. Preclinical investigations for AP-188, as part of their stroke clinical research program, are underway through a collaboration with Charles River Laboratories. Established in 2015, Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
Share Price
$0.29357476
Last synced: 2026-05-14
Market Cap
$1.02M
Change (1 day)
1.27%
Change (1 year)
-42.07%
Country
CA
Trade Algernon Pharmaceuticals Inc. (AGN)

Category

Dividend yield history for Algernon Pharmaceuticals Inc. (AGN)
Algernon Pharmaceuticals Inc. (stock symbol: AGN) dividend yield (TTM) as of 2026: 0
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Algernon Pharmaceuticals Inc. (AGN) from 2026 to 2026
Dividend Yield at the end of each year (TTM)
Year Dividend Yield Change
Not enough data for the provided dates.
Dividend yields (TTM) for similar companies or competitors